Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TIMOTHY L JACKSON

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1427070747
CMS profile
200771
Location
BEAVER, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$195.47

12 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $163.20 11
Education $32.27 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TIMOTHY L JACKSON

NPI 1427070747 · CMS profile ID 200771

Allopathic & Osteopathic Physicians / Internal Medicine

BEAVER, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427070747?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TIMOTHY L JACKSON, NPI 1427070747, CMS profile ID 200771. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427070747?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). TIMOTHY L JACKSON, NPI 1427070747, CMS profile ID 200771. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427070747?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
TIMOTHY L JACKSON, NPI 1427070747, CMS profile ID 200771, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1427070747?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

12 matching records · $195.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 12 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–12 of 12.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $11.6212/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736181271 CMS
Novo Nordisk Inc $32.2709/01/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744847051 CMS
Novo Nordisk Inc $13.9007/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745041875 CMS
Corcept Therapeutics $18.6904/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744761753 CMS
AstraZeneca Pharmaceuticals LP $12.9703/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736297699 CMS
GlaxoSmithKline, LLC. $15.6703/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738533643 CMS
Janssen Pharmaceuticals, Inc $12.5502/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719458831 CMS
Novo Nordisk Inc $14.0202/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744723237 CMS
Lilly USA, LLC $16.4701/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728673307 CMS
Astellas Pharma US Inc $13.7301/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718337493 CMS
GlaxoSmithKline, LLC. $17.2001/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738781385 CMS
GlaxoSmithKline, LLC. $16.3801/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738626129 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $260.46 19
PY2020 $195.47 12
PY2021 $95.34 6
PY2022 $222.89 13
PY2023 $111.20 6
PY2024 $44.96 2
PY2025 $109.48 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $503,145.38 229
PY2024 Principal investigator $594,169.25 24
PY2023 Principal investigator $199,257.41 109
PY2022 Principal investigator $75,190.78 47
PY2021 Principal investigator $41,602.59 77
PY2020 Principal investigator $45,172.38 58
PY2019 Principal investigator $122,329.81 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

109 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $3,500.00 12/20/2023 Non-covered Recipient Entity
Heritage Valley Multispecialty Group Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1046175137
Principal investigator 1 Chiesi USA, Inc. $895.00 12/13/2023 Non-covered Recipient Entity
HERITAGE VALLEY MULTISPECIALTY GROUP INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051619441
Principal investigator 1 Chiesi USA, Inc. $4,116.00 12/13/2023 Non-covered Recipient Entity
HERITAGE VALLEY MULTISPECIALTY GROUP INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051619447
Principal investigator 1 Novo Nordisk AS $3,680.37 11/27/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192747
Principal investigator 1 Chiesi USA, Inc. $11,284.00 11/09/2023 Non-covered Recipient Entity
HERITAGE VALLEY MULTISPECIALTY GROUP INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051616831
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.24 11/01/2023 Non-covered Recipient Entity
Hvmg Valley Internal Medicine
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1007650051
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,697.20 10/26/2023 Non-covered Recipient Entity
Hvmg Valley Internal Medicine
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1022134151
Principal investigator 1 Chiesi USA, Inc. $2,097.00 10/24/2023 Non-covered Recipient Entity
HERITAGE VALLEY MULTISPECIALTY GROUP INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051612285
Principal investigator 1 Novo Nordisk AS $3,047.76 10/23/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192731
Principal investigator 1 Novo Nordisk AS $1,136.43 09/22/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192659
Principal investigator 1 Novo Nordisk AS $23.06 09/22/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192689
Principal investigator 1 Novo Nordisk AS $23.06 09/13/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192717
Principal investigator 1 Novo Nordisk AS $23.06 09/08/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192703
Principal investigator 1 Chiesi USA, Inc. $4,993.00 08/31/2023 Non-covered Recipient Entity
HERITAGE VALLEY MULTISPECIALTY GROUP INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051605875
Principal investigator 1 PFIZER INC. $394.89 08/30/2023 Non-covered Recipient Entity
Heritage Valley Multispecialty Group Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1046085175
Principal investigator 1 Novo Nordisk AS $646.38 08/18/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007120755
Principal investigator 1 Novo Nordisk AS $2,076.00 08/18/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007120771
Principal investigator 1 PFIZER INC. $722.93 08/18/2023 Non-covered Recipient Entity
Heritage Valley Multispecialty Group Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1046232503
Principal investigator 1 Novo Nordisk AS $23.06 08/03/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192675
Principal investigator 1 Novo Nordisk AS $1,078.92 07/31/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007120735
Principal investigator 1 PFIZER INC. $20,970.24 07/26/2023 Non-covered Recipient Entity
Heritage Valley Multispecialty Group Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1046045799
Principal investigator 1 Novo Nordisk AS $23.06 07/11/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008679965
Principal investigator 1 PFIZER INC. $1,446.54 07/01/2023 Non-covered Recipient Entity
Heritage Valley Multispecialty Group Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1046337369
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007594495
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007594505
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007594515
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007594525
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007594535
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008679895
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008679913
Principal investigator 1 Novo Nordisk AS $9.99 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008679933
Principal investigator 1 Novo Nordisk AS $174.64 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008679949
Principal investigator 1 Novo Nordisk AS $7.99 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008793021
Principal investigator 1 Novo Nordisk AS $7.49 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008793037
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008793053
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008793069
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008793087
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008793103
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008793119
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008793137
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008793153
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008793171
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008793187
Principal investigator 1 Chiesi USA, Inc. $2,029.00 06/26/2023 Non-covered Recipient Entity
HERITAGE VALLEY MULTISPECIALTY GROUP INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051595975
Principal investigator 1 Chiesi USA, Inc. $2,029.00 06/26/2023 Non-covered Recipient Entity
HERITAGE VALLEY MULTISPECIALTY GROUP INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051595977
Principal investigator 1 Novo Nordisk AS $680.94 06/23/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007120719
Principal investigator 1 PFIZER INC. $320.00 06/23/2023 Non-covered Recipient Entity
HERITAGE VALLEY MEDICAL GROUP INC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1046102727
Principal investigator 1 PFIZER INC. $40.00 06/23/2023 Non-covered Recipient Entity
HERITAGE VALLEY MEDICAL GROUP INC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1046132771
Principal investigator 1 PFIZER INC. $5,208.32 06/03/2023 Non-covered Recipient Entity
Heritage Valley Multispecialty Group Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1045989573
Principal investigator 1 Novo Nordisk AS $1,384.83 05/26/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007120687
Principal investigator 1 Novo Nordisk AS $288.00 05/26/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007120703
Principal investigator 1 Novo Nordisk AS $23.06 05/25/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008793005
Principal investigator 1 PFIZER INC. $3,286.58 05/19/2023 Non-covered Recipient Entity
Heritage Valley Multispecialty Group Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1045998983
Principal investigator 1 PFIZER INC. $1,871.54 05/16/2023 Non-covered Recipient Entity
Heritage Valley Medical Group
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1046160295
Principal investigator 1 Novo Nordisk AS $1,384.83 04/26/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008680029
Principal investigator 1 Novo Nordisk AS $2,460.00 04/26/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008680049
Principal investigator 1 PFIZER INC. $1,446.54 04/21/2023 Non-covered Recipient Entity
Heritage Valley Multispecialty Group Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1046283147
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1006863671
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1006863681
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1006863691
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1006863703
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1006863713
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1006863721
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007291017
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007291029
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007291039
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007291049
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007291061
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1007291071
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192583
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192597
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192615
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192629
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192645
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008534371
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008534389
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008534405
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008534423
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008534439
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008534457
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008534473
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008534487
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008534505
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008534521
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008792869
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008792883
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008792905
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008792919
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008792935
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008792951
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008792969
Principal investigator 1 Novo Nordisk AS $24.95 04/05/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008792987
Principal investigator 1 PFIZER INC. $11,009.93 04/04/2023 Non-covered Recipient Entity
Heritage Valley Multispecialty Group Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1045943001
Principal investigator 1 Novo Nordisk AS $646.38 03/24/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192541
Principal investigator 1 Novo Nordisk AS $23.06 03/24/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008679997
Principal investigator 1 PFIZER INC. $19,292.10 03/24/2023 Non-covered Recipient Entity
Heritage Valley Multispecialty Group Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1046018673
Principal investigator 1 PFIZER INC. $935.77 03/22/2023 Non-covered Recipient Entity
Heritage Valley Medical Group
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1045942187
Principal investigator 1 PFIZER INC. $935.77 03/22/2023 Non-covered Recipient Entity
Heritage Valley Medical Group
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1046085159
Principal investigator 1 PFIZER INC. $935.77 03/22/2023 Non-covered Recipient Entity
Heritage Valley Medical Group
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1046344853
Principal investigator 1 Novo Nordisk AS $23.06 03/15/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008680013
Principal investigator 1 Novo Nordisk AS $23.06 03/10/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008679981
Principal investigator 1 Novo Nordisk AS $738.45 02/22/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008110973
Principal investigator 1 Novo Nordisk AS $23.06 02/14/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192569
Principal investigator 1 Novo Nordisk AS $23.06 02/02/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008192555
Principal investigator 1 Novo Nordisk AS $69.93 01/30/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008051625
Principal investigator 1 Novo Nordisk AS $1,327.32 01/25/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008051643
Principal investigator 1 PFIZER INC. $935.77 01/19/2023 Non-covered Recipient Entity
Heritage Valley Medical Group
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF07081532 AND OPEN LABEL ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS T2DM INADEQUATELY CONTROLLED ON METFORMIN AND SEPARATELY PF07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM No dispute reported 06/30/2026 1046345499
Principal investigator 1 Novo Nordisk AS $23.06 01/10/2023 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4321 No dispute reported 06/30/2026 1008051611
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $70,772.10 01/05/2023 Non-covered Recipient Entity
Hvmg Valley Internal Medicine
Phase II dose finding PoCC in CKD No dispute reported 06/30/2026 1022142481